Partial results from Dicot's phase 1 trial to be presented early next year
Press Release: Uppsala, December 15, 2023. Yesterday, the potency drug developer Dicot concluded the clinical part of the SAD, earlier than initially planned. Consequently, the company will be able to report these results already in the January-to-February transition. Results from the second and final part of the phase 1 trial are expected to be communicated in the second quarter of next year, as previously announced.Dicot's phase 1 trial of the potency drug candidate LIB-01 is placebo-controlled and double-blinded, with the primary objective of investigating the safety profile in humans.